Target Trial Emulation Confirms Safety of Same-Day COVID-19 and Influenza Vaccine Coadministration

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Annals of Internal Medicine, https://doi.org/10.7326/ANNALS-26-00217 
Dr. Yan Xie  et al.

Points

A large target trial emulation utilizing data from 2.5 million patients evaluated the short-term safety of coadministering seasonal influenza and variant-updated COVID-19 vaccines.
Researchers analyzed health records from the Department of Veterans Affairs database spanning a multi-year period from September 1, 2022, through August 26, 2025.
The study directly compared over 700,000 individuals receiving both vaccines at the same visit to more than 1.8 million patients receiving only the influenza vaccine.
Surveillance of 46 distinct adverse events during a 90-day follow-up window revealed no increased risk for cardiovascular, thrombotic, neurological, or immune-mediated disorders.
Safety outcomes remained consistently favorable across multiple variant-updated formulation eras including the bivalent, XBB-adapted, and contemporary KP-adapted COVID-19 vaccination periods.

Summary

This target trial emulation evaluated the short-term safety profile of same-day coadministration of COVID-19 and influenza vaccines compared to influenza vaccination alone. Utilizing database records from the U.S. Department of Veterans Affairs health care system, the study tracked 2.5 million patients vaccinated between September 1, 2022, and August 26, 2025. Given that variant-updated vaccine formulations and increasing population-level hybrid immunity may modify baseline clinical reactogenicity, this investigation sought to establish contemporary safety parameters for simultaneous administration across bivalent, XBB-adapted, and KP-adapted formulation periods.

The large-scale cohort analysis compared 700,000 individuals who underwent same-day coadministration against a control group of over 1.8 million individuals who received only the seasonal influenza vaccine. The researchers systematically tracked 46 potential adverse events over a predefined 90-day post-vaccination window, categorizing outcomes by physical manifestation and clinical severity. (Note: Specific confidence intervals and hazard ratios were not included in the primary source dataset).

The results demonstrated that simultaneous administration of the COVID-19 and influenza vaccines was not associated with an elevated risk of serious or clinically meaningful adverse events. No significant increases in risk were noted for neurological disorders, immune-mediated conditions, cardiovascular events, or thrombotic complications across all three updated COVID-19 formulation intervals. These findings robustly confirm the short-term safety of vaccine coadministration in immune-experienced adult populations, providing crucial empirical support to streamline ongoing public health immunization logistics and vaccine policy discussions.

Link to the article: https://www.acpjournals.org/doi/10.7326/ANNALS-26-00217

References

Xie, Y., Choi, T., & Al-Aly, Z. (2026). Adverse events after same-day covid-19 and influenza vaccination versus influenza vaccination alone: A target trial emulation. Annals of Internal Medicine, ANNALS-26-00217. https://doi.org/10.7326/ANNALS-26-00217